Clostridium difficile-associated diarrhea in the oncology patient

Kari Neemann, Alison Gail Freifeld

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

Clostridium difficile is the most common cause of nosocomial diarrhea, resulting in significant morbidity and mortality in hospitalized patients. Oncology patients are particularly at risk of this infection secondary to frequent exposure to known risk factors. In a population in which diarrhea is a common adverse effect of chemotherapeutic regimens, diagnosis can be challenging secondary to current limitations in testing to differentiate between colonization and active infection. Although several currently available antimicrobial therapies achieve resolution of symptoms in this population, further research is needed to determine which agent least affects the host intestinal microbiota, especially in times of neutropenia and mucosal barrier injury. The purpose of this article is to review the current literature on the epidemiology, pathogenesis, and management of C difficile-associated diarrhea in the oncology population.

Original languageEnglish (US)
Pages (from-to)25-30
Number of pages6
JournalJournal of oncology practice
Volume13
Issue number1
DOIs
StatePublished - Jan 1 2017

Fingerprint

Clostridium difficile
Diarrhea
Population
Neutropenia
Coinfection
Epidemiology
Morbidity
Mortality
Wounds and Injuries
Infection
Research
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Oncology(nursing)
  • Health Policy

Cite this

Clostridium difficile-associated diarrhea in the oncology patient. / Neemann, Kari; Freifeld, Alison Gail.

In: Journal of oncology practice, Vol. 13, No. 1, 01.01.2017, p. 25-30.

Research output: Contribution to journalReview article

@article{3b5b70f676864f4181fa46225265c601,
title = "Clostridium difficile-associated diarrhea in the oncology patient",
abstract = "Clostridium difficile is the most common cause of nosocomial diarrhea, resulting in significant morbidity and mortality in hospitalized patients. Oncology patients are particularly at risk of this infection secondary to frequent exposure to known risk factors. In a population in which diarrhea is a common adverse effect of chemotherapeutic regimens, diagnosis can be challenging secondary to current limitations in testing to differentiate between colonization and active infection. Although several currently available antimicrobial therapies achieve resolution of symptoms in this population, further research is needed to determine which agent least affects the host intestinal microbiota, especially in times of neutropenia and mucosal barrier injury. The purpose of this article is to review the current literature on the epidemiology, pathogenesis, and management of C difficile-associated diarrhea in the oncology population.",
author = "Kari Neemann and Freifeld, {Alison Gail}",
year = "2017",
month = "1",
day = "1",
doi = "10.1200/JOP.2016.018614",
language = "English (US)",
volume = "13",
pages = "25--30",
journal = "Journal of Oncology Practice",
issn = "1554-7477",
publisher = "American Society of Clinical Oncology",
number = "1",

}

TY - JOUR

T1 - Clostridium difficile-associated diarrhea in the oncology patient

AU - Neemann, Kari

AU - Freifeld, Alison Gail

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Clostridium difficile is the most common cause of nosocomial diarrhea, resulting in significant morbidity and mortality in hospitalized patients. Oncology patients are particularly at risk of this infection secondary to frequent exposure to known risk factors. In a population in which diarrhea is a common adverse effect of chemotherapeutic regimens, diagnosis can be challenging secondary to current limitations in testing to differentiate between colonization and active infection. Although several currently available antimicrobial therapies achieve resolution of symptoms in this population, further research is needed to determine which agent least affects the host intestinal microbiota, especially in times of neutropenia and mucosal barrier injury. The purpose of this article is to review the current literature on the epidemiology, pathogenesis, and management of C difficile-associated diarrhea in the oncology population.

AB - Clostridium difficile is the most common cause of nosocomial diarrhea, resulting in significant morbidity and mortality in hospitalized patients. Oncology patients are particularly at risk of this infection secondary to frequent exposure to known risk factors. In a population in which diarrhea is a common adverse effect of chemotherapeutic regimens, diagnosis can be challenging secondary to current limitations in testing to differentiate between colonization and active infection. Although several currently available antimicrobial therapies achieve resolution of symptoms in this population, further research is needed to determine which agent least affects the host intestinal microbiota, especially in times of neutropenia and mucosal barrier injury. The purpose of this article is to review the current literature on the epidemiology, pathogenesis, and management of C difficile-associated diarrhea in the oncology population.

UR - http://www.scopus.com/inward/record.url?scp=85011371140&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011371140&partnerID=8YFLogxK

U2 - 10.1200/JOP.2016.018614

DO - 10.1200/JOP.2016.018614

M3 - Review article

C2 - 28084880

AN - SCOPUS:85011371140

VL - 13

SP - 25

EP - 30

JO - Journal of Oncology Practice

JF - Journal of Oncology Practice

SN - 1554-7477

IS - 1

ER -